Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon titration in Chinese Alzheimer's disease patients
NCT01948791Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01948791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01948791.